Watching infants after mavacamten use in pregnancy
Treatments studied
Part of Heart & circulation clinical trials.
This study follows people who took mavacamten during pregnancy or breastfeeding to better understand infant outcomes. It may help doctors and families know what to expect and improve safety guidance.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You took at least 1 dose of mavacamten during pregnancy (from about 4 months before conception through delivery) and/or during breastfeeding (up to 12 months or weaning)
- You are 15 years or older when you enroll
- You can give consent (or an ethics board approves a waiver)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well mavacamten works in real life for adults with obstructive hypertrophic cardiomyopathy, a condition where the heart muscle is thickened and blocks blood flow. It may help improve symptoms like shortness of breath or chest pain.
This study looks at adults with a heart condition called obstructive hypertrophic cardiomyopathy. It tracks what happens after they start taking the medicine mavacamten, to learn more about its effects and how it works in real life.
This study looks at whether adjusting the dose of mavacamten based on heart function helps people with obstructive hypertrophic cardiomyopathy feel better and have fewer side effects. It is for people who are already on mavacamten and want to see if a personalized dose approach works.
This study tracks the safety of Mavacamten in people with obstructive hypertrophic cardiomyopathy (a condition where the heart muscle thickens and blocks blood flow). It helps doctors understand how the drug works in everyday use in Japan.
This study looks at how mavacamten (a heart medication) works for people with obstructive hypertrophic cardiomyopathy (HCM)—a condition where heart muscle becomes too thick. Researchers will review medical records and ask patients about their experiences with the treatment.
This study tests whether the drug mavacamten (Camzyos) improves blood flow in the heart's small vessels for people with obstructive hypertrophic cardiomyopathy. You will take mavacamten as prescribed and have a PET/CT scan to measure your heart's blood flow reserve.
Hear when a new Breastfeeding trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.